ArticleNPJ precision oncology2026
Spatial-temporal recurrence patterns of grade 4 glioma using deep learning integrated multiparametric MRI and molecular pathology.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Grade 4 glioma is inherently lethal due to inevitable recurrence. Current radiotherapy guidelines recommend uniform target volume margins, disregarding molecular and clinical variables. We hypothesized that spatiotemporal recurrence may be predicted by molecular and phenotypic features present already at diagnosis. We analyzed 390 paired MRIs of grade 4 gliomas from Norwegian multi-centers and TCIA (2015-2025). Deep learning segmentation identified contrast-enhancing (CEcore) and non-enhancing (NE) tumor compartments and afflicted anatomical regions. We quantified primary CEcore/NE volume ratio, anatomical tumor trajectories, and spatiotemporal progression using Hausdorff-95-analyzed in relation to survival, MGMT, IDH, age, extent of resection, sex, and anatomical location, using machine learning and Cox regression. Primary tumor composition was independently prognostic: CEcore/NE volume ratio ≤0.324 predicted improved overall survival (adjusted HR = 0.56, 95% CI 0.37-0.84, p = 0.006), independent of age, MGMT-status, and individual compartments. Within IDH-wildtype, MGMT-unmethylated patients, low volume ratio ≤0.324 demonstrated a 4.3 months survival benefit (median 17.6 vs 13.3 months, p = 0.0209). Longer time to progression correlated with increased HD95 distances (p < 0.03). Tumors originating in occipital lobe had highest propensity to migrate to new sites (57.1%) and the shortest time to progression (adjusted HR = 1.90, p = 0.026). These findings support molecular-demographic-anatomical risk stratification that may inform personalized margin-determination in radiotherapy planning.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.